Found 22 Small Cell Lung Cancer trials
A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head or Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
This study evaluates the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer.
The Investigation Device Exemption (IDE) study will evaluate the safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed …
This study aims to provide much-needed data regarding how to optimally treat vulnerable older adults with metastatic NSCLC.
The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.Participants for …
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent …
This study is a retrospective and prospective medical record review of patients with NSCLC harboring EGFR ex20ins mutations treated at cancer centers participating in ATOMIC.
This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety.
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines MK-4830 in combination with pembrolizumab in participants with PD-L1 positive NSCLC.
